A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma
NCT04370405
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
123
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma, Follicular
Interventions
DRUG:
YY-20394
Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.